Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

AIM Rule 26

Regulatory news

Why Invest

Presentations

Home

Media

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

NM_CRS-poster_Onco_IlonaKubajewska_270622.pdf

In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene therapy delivery platform in cancer treatment.

Introducing exogenous genetic material to a cell alters its protein expression, which presents the challenge of protecting sensitive nucleic acids from enzymatic degradation in the body and to deliver them to a target site whilst minimising the off-target side effects.

In this study, N4 Pharma and Nanomerics formulated colloidally stable Nuvec-TNF-α pDNA polyplexes which successfully mediated gene transfer to the cells and translation to the functional cytokine in vitro, as well as generating an anti-tumour response in vivo in a mouse tumour model which increased mice survival.

As a result, the Nuvec® nanoparticle delivery system has demonstrated its potential to deliver tumoricidal plasmids in vivo and therefore presents a viable alternative for clinical use in cancer therapies.

Poster Presentation: Nuvec® as a gene therapy platform in oncology